<DOC>
	<DOCNO>NCT02616640</DOCNO>
	<brief_summary>This multicenter , multicountry , open-label , Phase 1b study dose find well parallel cohort dose expansion ( ) determine recommend dose regimen durvalumab either monotherapy combination pomalidomide ( POM ) without low dose dex subject Relapsed Refractory Multiple Myeloma ( RRMM ) . The study consist dose-finding portion well parallel dose expansion portion determine optimal dose regimen .</brief_summary>
	<brief_title>A Study Determine Dose Regimen Durvalumab Monotherapy Combination With Pomalidomide With Without Dexamethasone Subjects With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Has confirm diagnosis active multiple myeloma measurable disease . Must undergone prior treatment ≥2 treatment line antimyeloma therapy Must fail last line treatment ( refractory last line treatment ) . Must achieve least stable disease ( SD ) least 1 cycle treatment least 1 prior antimyeloma regimen develop Progressive disease ( PD ) ( relapse ) Prior antimyeloma treatment must include lenalidomide AND proteasome inhibitor alone combination . Has performance status 0 , 1 , 2 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale . Has nonsecretory oligosecretory multiple myeloma Has prior antimyeloma therapy within 2 week prior study Day 1 Has undergone prior organ allogeneic hematopoetic stem cell transplantation Has receive previous therapy pomalidomide achieve least stable disease Has receive prior therapy antiprogrammed cell death 1 receptor ( antiPD1 ) , antiprogrammed deathligand 1 ( antiPDL1 ) , antiprogrammed deathligand 2 ( antiPDL2 ) , antiCD137 , anticytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) antibody ( include ipilimumab antibody drug specifically target Tcell costimulation checkpoint pathway ) . Has receive prior treatment monoclonal antibody within 5 halflives Study Day 1 Has receive investigational agent within 28 day 5 halflives ( whichever longer ) Study Day 1 Has receive live , attenuated vaccine within 30 day prior Study Day 1 Had rash ≥ Grade 3 prior thalidomide , lenalidomide , pomalidomide therapy Has history anaphylaxis hypersensitivity thalidomide , lenalidomide , POM , dex Has peripheral neuropathy ≥ Grade 2 Has know additional malignancy progress require active treatment ( except basal cell carcinoma skin , squamous cell carcinoma skin , situ cervical cancer undergone potentially curative therapy ) . Is positive human immunodeficiency virus ( HIV ) , chronic active hepatitis B active hepatitis A C Has prior history malignancy , MM , unless subject free disease ≥ 5 year ( exception Basal cell carcinoma skin , Squamous cell carcinoma skin , Carcinoma situ cervix , Carcinoma situ breast , Incidental histologic find prostate cancer [ T1a T1b ] prostate cancer curative ) Has clinical evidence central nervous system ( CNS ) pulmonary leukostasis , disseminate intravascular coagulation , CNS multiple myeloma Has clinically significant cardiac disease Is female pregnant , nursing , breastfeeding , intend become pregnant participation study Is current smoker</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>MEDI4736</keyword>
	<keyword>Durvalumab</keyword>
	<keyword>Pomalidomide ( POM )</keyword>
	<keyword>Dexamethasone ( DEX )</keyword>
	<keyword>PD-L1</keyword>
</DOC>